Taşkın ŞENTÜRK, Gökhan SARGIN, Songül ÇİLDAĞ

Allerjen Spesifik İmmünoterapi Ailevi Akdeniz Ateşi Ataklarını Tetikleyebilir mi?

Allerjen spesifik immünoterapi kişide spesifik allerjen maruziyeti sonrasında gelişebilecek allerjik semptomları ve ilaç kullanım ihtiyacını azaltmaya yönelik bir tedavi şeklidir. Atopik dermatit, allerjik astım, allerjik rinit ve böcek sokmalarında oldukça etkin bir tedavi şekli olmakla birlikte allerjen spesifik immünoterapi ile ilişkili ciddi yan etkiler de oluşabilmektedir. Allerjen spesifik immünoterapinin, immün sistem üzerinde yapmış olduğu değişiklikler nedeniyle, otoimmün hastalıklar gibi immün sistem aracılığı ile gelişen enflamatuvar hastalık oluşumunu da etkileyebileceği düşünülmektedir. Burada sunduğumuz olgu, allerjen spesifik immünoterapi tedavisi sırasında Ailesel Akdeniz Ateşi atağı semptomları gelişen, bildirilmiş ilk olgu sunumudur.

Can Allergen Specific Immunotherapy Induce Familial Mediterranean Fever Attacks?

Allergen-specific immunotherapy is a treatment aimed to reduce allergic symptoms and need for medication use after exposure to specific allergens. Allergen-specific immunotherapy is the only curative treatment that can change the natural course of allergic diseases. Although, allergen-specific immunotherapy is quite effective in the treatment of atopic dermatitis, allergic asthma, allergic rhinitis, and insect bites, serious treatment-related side effects may still occur. Since allergen-specific immunotherapy can cause changes in the immune system, it is theoretically possible that it can also affect immune system mediated inflammatory diseases such as autoimmune diseases. This is the first case report of an occurrence of Familial Mediterranean Fever attacks during allergen-specific immunotherapy.

PDF

___

Bousquet J, Lockey RF, Malling HJ. Allergen immunotherapy: therapeutical vaccines for allergic diseases A WHO Position Paper. Allergy 1998; 53(Suppl 54): 1-15.
Akdis CA, Akdis M. Mechanisms of allergen-specific immunotherapy. J Allergy Clin Immunol 2011; 127: 18-27.
Gri G, Piconese S, Frossi B, Manfroi V, Merluzzi S, Tripodo C, et al. CD4+CD25+ regulatory T cells suppress mast cell degranulation and allergic responses through OX40-OX40L interaction. Immunity 2008; 29: 771-81.
Kearley J, Barker JE, Robinson DS, Lloyd CM. Resolution of airway inflammation and hyperreactivity after in vivo transfer of CD4+CD25+ regulatory T cells is interleukin 10 dependent. J Exp Med 2005; 202: 1539-47.
Kearley J, Robinson DS, Lloyd CM. CD4+CD25+ regulatory T cells reverse established allergic airway inflammation and prevent airway remodeling. J Allergy Clin Immunol 2008; 122: 617-24.
Meiler F, Klunker S, Zimmermann M, Akdis CA, Akdis M. Distinct regulation of IgE, IgG4 and IgA by T regulatory cells and toll-like receptors. Allergy 2008; 63: 1455-63.
Cox L, Larenas-Linnemann D, Lockey RF, Passalacqua G. Speaking the same language: The World Allergy Organization Subcutaneous Immunotherapy Systemic Reaction Grading System. J Allergy Clin Immunol 2010; 125: 569-74.
Jacobsen L, Niggemann B, Dreborg S, Ferdousi HA, Halken S, Høst A, et al. Specific immunotherapy has long-term preventive effect of seasonal and perennial asthma: 10-year follow-up on the PAT study. Allergy 2007; 62: 943-8.
Turkcapar N, Kinikli G, Sak SD, Duman M. Specific immunotherapy induced Sjögren’s syndrome. Rheumatol Int 2005; 26: 182-4.
Nakajima H, Ohtsuka S, Nishina T, Sugino M, Kimura F, Hanafusa T, et al. Multiple sclerosis after allergen-specific immunotherapy and influenza vaccination. Eur Neurol 2003; 50: 248-9.
Morfin Maciel BM, Castillo Morfin BM. Scleroderma realted to specific immunotherapy. A report of a case. Rev Alerg Mex 2009; 56: 136-45.
Quirce S, Fernandez Rivas M, Losada E, de la Hoz B, Fraj J, Alvarez Cuesta E. Recurrent pericarditis: a rare complication of allergen immunotherapy. Allergy 1992; 47: 343-5.
Phanuphak P, Kohler PF. Onset of polyarteritis nodosa during allergic hyposensitization treatment. Am J Med 1980; 68: 47985.
Wing K, Sakaguchi S. Allerjide potansiyel immünoterapi için regülatör T hücreler. Curr Opin Allergy Clin Immunol 2006; 1: 4.
Akdiş CA, Blaser K. IL-1 induced anergy in peripheral T cell and reactivation by. T Klin J Allergy-Asthma 2000; 2: 42-4.
Larche M. Regulatory T cells in allergy and asthma. Chest 2007; 132: 1007-14.
Sohar E, Gafni J, Pras M, Heller H. Familial Mediterranean fever. A survey of 470 cases and review of the literature. Am J Med 1967; 43: 227-53.
Akarsu AN, Saatci U, Ozen S, Bakkaloglu A, Beşbaş N, Sarfarazi M. Genetic linkage study of familial Mediterranean fever (FMF) to 16pl3.3 and evidence for genetic heterogeneity in the Turkish population. J Med Genet 1997; 34: 573-8.
Amyloidosis FMF and MEFV gene. Amyloid: Int J Exp Clin Invest 2000; 7: 289-93.
Gershoni-Baruch R, Shinawi M, Leah K, Badarnah K, Brik R. Familial Mediterranean fever: prevalence, penetrance and genetic drift. Eur J Hum Genet 2001; 9: 3-7.
Yilmaz E, Özen S, Balci B, Duzova A, Topaloglu R, Besbas N, et al. Mutation frequency of familial mediterranean fever and evidence of a high a carrier rate in the Turkish population. Eur J Hum Genet 2001; 9: 553-5.
Yazıcı H, Özdoğan H. Familial Mediterranean fever in Turkey. In: Sohar E, Gafni J, Pras M, eds. Proceeding of the I. International Conference on FMF, Tel Aviv: Freund; 1997.p.66-71.
Eisenberg S, Aksentijevich I, Deng Z, Kastner DL, Matzner J. Diagnosis of Familial Mediterranean Fever by a Molecular Genetics Method. Ann Int Med 1998; 129: 243-51.
Pras M. Familial Mediterranean fever: from the clinical syndrome to the cloning of the pyrin gene. Scand J Rheumatol 1998; 27: 92-7.
Goldfinger SE. Colchicine for Familial Mediterranean Fever. New Eng J Med 1972; 287: 1302.
No authors listed. Ancient missense mutations in a new member of the RoRet gene family are likely the cause familial Mediteranean fever. The International FMF Consortium. Cell 1997; 90: 797-807.
Ben-Chetrit E, Levy M. Familial Mediterranean fever. Lancet 1998; 351: 659-64.
Notarnicola C, Didelot MN, Kone-Paut I, Seguret F, Demaille J, Toitou I. Reduced MEFV messenger RNA expression in patient with familial Mediterranean fever. Arthritis Rheum 2002; 46: 2785-93.
Barakat MH, Malhas LN, Gumaa KK. Catecholamine metabolism in recurrent hereditary polyserositis. Pathogenesis of acute inflammation: The retention leakage hypothesis. Biomed Pharmacother 1989; 43: 763-9.
Matzner Y, Ayesh SK, Hochner-Celniker D, Ackerman Z, Ferne M. Proposed mechanizm of inflammatory attacks in familial Medeterranean fever. Arch Intern Med 1990; 150: 1289-91.
Direskeneli H, Ozdogan H, Korkmaz C, Akoglu T, Yazici H. Serum soluble intercellular adhesion molecule-1 and interleukin 8 levels in Famial Mediterranean Fever. J Rheumatol 1999:26.
. Haznedaroglu S, Oztürk MA, Sancak B, Goker B, Onat AM, Bukan N, et al. Serum interleukin 17 and interleukin 18 levels in familial Mediterranean fever. Clin Exp Rheumatol 2005; 23 (4 Suppl 38): 77-80.
Schwarzenberger P, La Russa V, Miller A, Ye P, Huang W, Zieske A, et al. IL-17 stimulates granulopoiesis in mice: use of an alternate, novel gene therapy- derived method for in vivo evaluation of cytokines. J Immunol 1998; 161: 6383-9.
Witowski J, Pawlaczyk K, Breborowicz A, Scheuren A, KuzlanPawlaczyk M, Wisniewska J, et al. IL-17 stimulates intraperitoneal neutrophil infiltration through the release of GRO alpha chemokine from mesothelial cells. J Immunol 2000; 165: 581421.